🇺🇸 Trimetazidine hydrochloride in United States

271 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 271

Most-reported reactions

1. Fall — 54 reports (19.93%)
2. Drug Interaction — 29 reports (10.7%)
3. Confusional State — 25 reports (9.23%)
4. Oedema Peripheral — 25 reports (9.23%)
5. Renal Failure — 25 reports (9.23%)
6. Hyponatraemia — 24 reports (8.86%)
7. Malaise — 24 reports (8.86%)
8. Dizziness — 22 reports (8.12%)
9. Dyspnoea — 22 reports (8.12%)
10. Somnolence — 21 reports (7.75%)

Source database →

Frequently asked questions

Is Trimetazidine hydrochloride approved in United States?

Trimetazidine hydrochloride does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Trimetazidine hydrochloride in United States?

The First Affiliated Hospital of Zhengzhou University is the originator. The local marketing authorisation holder may differ — check the official source linked above.